The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
https://www.imperial.ac.uk/stories/alumni-awards-2022-stephen/
https://www.genengnews.com/topics/omics/microbiome-drugs-multiplying-recent-gains/
https://twitter.com/SericaEnergyUK/status/1473698894626398212
#SQZ - With 2022 fast approaching, the completion of the BKR deal with BP coming to an end, Nat Gas prices at record highs & 100% Revenues to Serica on the horizon ‘Significant Returns’ are in store…
This came up on a google search,
The Hut Group - Betavillehttps://betaville.co.uk › tags › the-hut-group
The Hut Group, the London-listed e-commerce retail giant, is rumoured to be working on a deal that could see the company raise up to £500 million of fresh ...
ODEY ASSET MANAGEMENT LLP short position in METRO BANK PLC down -0.15% to 1.87% #MTRO
https://twitter.com/shortdatauk/status/1456319094504886275
https://www.thearmchairtrader.com/quantum-blockchain-share-price-forecast-27102021/
https://www.dailymail.co.uk/news/article-10087059/China-makes-mockery-climate-targets-plans-build-coal-power-stations.html
July Ndlovu, the boss of the South African coal mine Thungela, said the demand for coal production will last for the next two decades.
Inlovu told Radio 4's Today programme that while Europe and the US will be at the forefront of the transition from coal toward renewable energies, countries such as China and India - which have far younger fossil fuel infrastructure - will follow much later.
From Linkedin,
About,
Senior pharma executive with over 30 years’ experience predominantly in global regulatory affairs, but including clinical research and commercial, gained in large and small Pharma as well as novel service companies.
Proven expertise at deriving and delivering regulatory affairs strategy for project portfolios across the lifecycle from late research/preclinical, through marketing authorisation to post-approval, in multiple therapeutic areas (including anti-infective, oncology, CNS and cardiovascular; biologics and NMEs,) and regions (EU, US and Japan). Particular expertise in leveraging regulatory strategy as a core business driver to accelerate patient access to innovative therapies.
Experienced industry leader and Board member in a variety of business models, including internal and external global resource management, financial management and HR. Co-founder and executive director of a global drug development services company (PLC).
Power crunch looms in India as coal stocks reach crisis point.
https://www.ft.com/content/a3ca4eaa-9ecc-4a81-ad53-4902fae4bd61
Thungela from 10.30 minutes in
https://youtu.be/8xX2IxTJK9Q
https://twitter.com/Synairgenplc/status/1442871156000710657
We’re thrilled to be shortlisted for the
@PharmaScrip
#ScripAwards Clinical Advance of the Year in the Covid-19 Pandemic Special Recognition category. Years of respiratory expertise enabled our team to pivot with laser focus on the global need and potential of #SNG001.